TR200003161T2 - Poliol-IFN-Beta konjugatları - Google Patents

Poliol-IFN-Beta konjugatları

Info

Publication number
TR200003161T2
TR200003161T2 TR2000/03161T TR200003161T TR200003161T2 TR 200003161 T2 TR200003161 T2 TR 200003161T2 TR 2000/03161 T TR2000/03161 T TR 2000/03161T TR 200003161 T TR200003161 T TR 200003161T TR 200003161 T2 TR200003161 T2 TR 200003161T2
Authority
TR
Turkey
Prior art keywords
ifn
polyol
peg
conjugates
beta conjugates
Prior art date
Application number
TR2000/03161T
Other languages
English (en)
Inventor
El Tayar Nabil
J. Roberts Michael
Harris Milton
Sawlivich Wayne
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200003161T2 publication Critical patent/TR200003161T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEG ünitesi, insan IFN- Cys17 ile kovalent bag yapan PEG-IFN- konjugatlari bir tiolreaktif PEGilasyon ajani kullanimi ile site spesifik PEGilasyon prosesi üzerinden üretilir. Enfeksiyon, tümör ve otoimün ve enflamatör hastaliklarin tedavi edilmesine yönelik bir farmakotik kompozisyon ve bir metot da temin edilir. Bu bulus, PEG ünitelerinin bir polipeptide ve daha özel anlamda IFN- 'ya seri sekilde, adim adim eklenmesi metodu ile de ilgilidir. (SEKIL 1)
TR2000/03161T 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları TR200003161T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
TR200003161T2 true TR200003161T2 (tr) 2001-01-22

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/01751T TR200101751T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları
TR2000/03161T TR200003161T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/01751T TR200101751T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları

Country Status (31)

Country Link
US (3) US6638500B1 (tr)
EP (2) EP1421956B1 (tr)
JP (2) JP4574007B2 (tr)
KR (1) KR100622796B1 (tr)
CN (2) CN100335503C (tr)
AR (1) AR020070A1 (tr)
AT (2) ATE275422T1 (tr)
AU (1) AU762621B2 (tr)
BG (2) BG64694B1 (tr)
BR (1) BR9910023A (tr)
CA (2) CA2330451A1 (tr)
CY (1) CY1108022T1 (tr)
CZ (2) CZ298579B6 (tr)
DE (2) DE69920002T2 (tr)
DK (2) DK1421956T3 (tr)
EA (2) EA003789B1 (tr)
EE (1) EE05214B1 (tr)
ES (2) ES2285286T3 (tr)
HK (2) HK1038194A1 (tr)
HU (1) HUP0300548A3 (tr)
IL (1) IL139286A (tr)
NO (2) NO329749B1 (tr)
NZ (1) NZ507456A (tr)
PL (2) PL193352B1 (tr)
PT (2) PT1075281E (tr)
SI (2) SI1421956T1 (tr)
SK (2) SK286654B6 (tr)
TR (2) TR200101751T2 (tr)
TW (2) TWI232882B (tr)
UA (2) UA66857C2 (tr)
WO (1) WO1999055377A2 (tr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CA2343094A1 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
EE05201B1 (et) * 1998-10-16 2009-08-17 Biogen Idec Ma Inc. Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
WO2000064484A2 (en) * 1999-04-23 2000-11-02 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (tr) * 1999-10-15 2001-08-21
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
CN1630530A (zh) 2002-01-18 2005-06-22 比奥根艾迪克Ma公司 聚亚烷基聚合物及其用途
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1667708B9 (en) 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
BR0317752A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
EP2085470B1 (en) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
EP1748788A1 (en) 2004-05-17 2007-02-07 Ares Trading S.A. Hydrogel interferon formulations
EP1750751B1 (en) 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
MXPA06014079A (es) 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2006069388A2 (en) 2004-12-21 2006-06-29 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
CA2594561C (en) * 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
AU2006278490A1 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Conjugates of a G-CSF moiety and a polymer
LT1917276T (lt) 2005-08-26 2018-05-25 Ares Trading S.A. Glikozilinto interferono beta gavimo būdas
CN101282740A (zh) 2005-09-01 2008-10-08 阿雷斯贸易股份有限公司 视神经炎的治疗
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5313129B2 (ja) * 2006-05-02 2013-10-09 アロザイン， インコーポレイテッド 非天然アミノ酸置換ポリペプチド
PL2026832T3 (pl) 2006-05-24 2012-08-31 Merck Serono Sa Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CN101878043A (zh) 2007-12-20 2010-11-03 默克雪兰诺有限公司 PEG-干扰素-β制剂
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
WO2012007324A2 (en) 2010-07-15 2012-01-19 Novo Nordisk A/S Stabilized factor viii variants
WO2012035050A2 (en) 2010-09-15 2012-03-22 Novo Nordisk A/S Factor viii variants having a decreased cellular uptake
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
BR112014007766B1 (pt) * 2011-10-01 2022-05-10 Glytech, Inc Polipeptídeo glicosilado, método para fabricação do mesmo e composição farmacêutica
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013129549A1 (ja) 2012-02-29 2013-09-06 東レ株式会社 体腔液貯留抑制剤
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
KR101671501B1 (ko) * 2014-07-24 2016-11-03 에이비온 주식회사 페길화된 인터페론-베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
RS61128B1 (sr) 2014-08-19 2020-12-31 Biogen Ma Inc Postupak pegilacije
KR20170141692A (ko) 2015-05-01 2017-12-26 알리스타 파마슈티컬즈, 인크. 안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
RS60943B1 (sr) * 2015-06-19 2020-11-30 Eisai R&D Man Co Ltd Cis80 konjugovani imunoglobulini
CN110753556A (zh) * 2017-04-17 2020-02-04 科罗拉多州立大学董事会法人团体 治疗同型半胱氨酸尿症的酶替代疗法优化
EP3919128A4 (en) 2019-01-28 2023-01-11 Toray Industries, Inc. POLYETHYLENE GLYCOL MODIFIED BODY FOR HEPATORYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF
EP3964266A4 (en) 2019-01-28 2022-12-28 Toray Industries, Inc. POLYETHYLENE GLYCOL MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
CN1103782C (zh) 1994-03-31 2003-03-26 安姆根有限公司 单聚乙二醇化的mgdf多肽
KR100384353B1 (ko) * 1994-05-18 2003-10-04 네크타르 테라퓨틱스 인터페론의건조분말제형을제조하기위한방법및조성물
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
EE200000614A (et) 2002-04-15
AU762621B2 (en) 2003-07-03
US20070141620A1 (en) 2007-06-21
PL196533B1 (pl) 2008-01-31
JP2010184929A (ja) 2010-08-26
IL139286A (en) 2005-12-18
AU3767499A (en) 1999-11-16
DE69920002T2 (de) 2005-09-22
ES2224649T3 (es) 2005-03-01
CZ298579B6 (cs) 2007-11-14
UA66857C2 (uk) 2004-06-15
HK1038194A1 (en) 2002-03-08
NZ507456A (en) 2003-10-31
DE69920002D1 (de) 2004-10-14
SI1421956T1 (sl) 2007-10-31
BG65046B1 (bg) 2007-01-31
NO332224B1 (no) 2012-07-30
ATE275422T1 (de) 2004-09-15
HK1076115A1 (en) 2006-01-06
PT1421956E (pt) 2007-07-13
AR020070A1 (es) 2002-04-10
EP1075281A2 (en) 2001-02-14
SK286217B6 (sk) 2008-05-06
CN1637020A (zh) 2005-07-13
CN1187094C (zh) 2005-02-02
ES2285286T3 (es) 2007-11-16
SI1075281T1 (en) 2005-02-28
KR100622796B1 (ko) 2006-09-13
JP2002512983A (ja) 2002-05-08
JP4574007B2 (ja) 2010-11-04
WO1999055377A3 (en) 1999-12-29
IL139286A0 (en) 2001-11-25
EA200001111A1 (ru) 2001-04-23
CZ298597B6 (cs) 2007-11-21
EP1421956B1 (en) 2007-06-27
UA79430C2 (en) 2007-06-25
PT1075281E (pt) 2004-11-30
US7357925B2 (en) 2008-04-15
CZ20003995A3 (en) 2001-06-13
HUP0300548A3 (en) 2005-07-28
NO329749B1 (no) 2010-12-13
CN1302209A (zh) 2001-07-04
EA003789B1 (ru) 2003-10-30
US20040043002A1 (en) 2004-03-04
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
TR200101751T2 (tr) 2002-05-21
PL344490A1 (en) 2001-11-05
CA2565375A1 (en) 1999-11-04
CA2330451A1 (en) 1999-11-04
NO20005337L (no) 2000-12-28
NO20005337D0 (no) 2000-10-23
KR20010071158A (ko) 2001-07-28
TWI232882B (en) 2005-05-21
BG109291A (en) 2006-04-28
ATE365563T1 (de) 2007-07-15
US7700314B2 (en) 2010-04-20
DE69936409D1 (de) 2007-08-09
EA005495B1 (ru) 2005-02-24
CN100335503C (zh) 2007-09-05
EP1421956A1 (en) 2004-05-26
SK286654B6 (sk) 2009-03-05
TWI266800B (en) 2006-11-21
CY1108022T1 (el) 2013-09-04
PL193352B1 (pl) 2007-02-28
WO1999055377A9 (en) 2000-03-02
DK1075281T3 (da) 2005-01-03
NO20100324L (no) 2000-12-28
WO1999055377A2 (en) 1999-11-04
BG64694B1 (bg) 2005-12-30
HUP0300548A2 (hu) 2003-06-28
DE69936409T2 (de) 2008-04-17
DK1421956T3 (da) 2007-10-01
BG104871A (en) 2001-07-31
BR9910023A (pt) 2000-12-26
SK16222000A3 (sk) 2001-04-09
US6638500B1 (en) 2003-10-28
EA200300382A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
TR200001615T2 (tr) Polietilen Glikol-Grf konjugatlarının yere-özel hazırlanması.
EP0423201A4 (en) Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DK0851925T3 (da) Humane Væksthormonvarianter
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
DE69910216D1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
TR200000015T2 (tr) Bileşikler ve metodlar
ATE332918T1 (de) Neoglycoproteine
EP0973819A4 (en) NON-ANTI-ACTIVE BRANCHING POLYMER CONJUGATES
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
ATE197903T1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
TWI266801B (en) Polyol-IFN-beta conjugates
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen